Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDirecta Plus Regulatory News (DCTA)

  • This share is currently suspended. It was suspended at a price of 6.75
  • There is currently no data for DCTA

New Safety Test

19 Apr 2021 07:00

RNS Number : 8065V
Directa Plus PLC
19 April 2021
 

This is a Reach announcement and the information contained is not considered to be material or to have a significant impact on management's expectations of the Company's performance. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

19 April 2021

 

Directa Plus plc

("Directa Plus" or the "Company")

 

New G+ Coating for Fabrics Dermatologically Tested

 

Human patch test results establish coating as suitable for skin contact

 

Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, announces that the Company's new G+® graphene coating for fabrics has been tested by an independent third party laboratory and found to be suitable for human skin contact. Since 2014, Directa Plus has commissioned 28 tests on different morphologies of G+® graphene, all of which have certified the absence of any negative impacts on biological systems.

 

The latest test was a human patch test, using volunteers, to assesses any potential side effects (skin erythema and oedema reactions) that may occur after applying the G+® product and to evaluate whether the product is safe for consumer use. The results showed zero erythema and oedema reactions across all subjects participating in the test and the G+® coated fabric was reported to be 'dermatologically tested' and non-irritating.

 

The G+® coating has been developed specifically for the automotive, upholstery, interior design, accessories and consumer electronics markets. It is thermally and electrically conductive, antibacterial and antiviral (certified to be anti-sars cov-2), UV and abrasion-resistant and can be applied to a wide variety of substrates, from natural and artificial fabrics to non-woven and microfiber, as well as felt and leather.

 

Giulio Cesareo, Chief Executive of Directa Plus, commented: "As always, our products are tested to the highest possible standards before releasing them to our target markets. Because our products are dermatologically tested to be non-toxic and hypoallergenic, Directa's business partners can develop innovative new products knowing that they will be safe for their own consumers."

 

For further information please visit http://www.directa-plus.com/ or contact:

 

Directa Plus plc

+39 02 36714458

Giulio Cesareo, CEO

 

Cenkos Securities plc (Nominated Adviser and Joint Broker)

+44 131 220 6939

Neil McDonald / Pete Lynch

 

N+1 Singer (Joint Broker)

+44 20 7496 3069

Rick Thompson / Phil Davies

 

Tavistock (Financial PR and IR)

+44 20 7920 3150

Simon Hudson / Edward Lee

 

 

About Directa Plus

Our focus is principally on the two sectors in which we have strong commercial advantage through developed and launched products and a technological lead: environmental (based on our Grafysorber® product), textiles (based on our G+ products) and more recently, lithium-sulphur batteries. In addition, we will continue to pursue opportunities in elastomers and composites (including tyres and asphalt), also using our G+ products. All our products are hypoallergenic, non-toxic and sustainably produced.

 

-ends-

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUWRBRAUUSAAR
Date   Source Headline
28th May 20267:00 amRNSCancellation - Directa Plus plc
27th Apr 20266:00 pmRNSDirecta Plus
27th Apr 20263:21 pmRNSAppointment of Administrators
14th Apr 20267:00 amRNSUpdate on Funding
13th Apr 20267:43 amRNSUpdate on Further Funding
13th Apr 20267:42 amRNSSuspension - Directa Plus PLC
30th Mar 20267:00 amRNSUpdate on Funding
20th Mar 20267:00 amRNSAIM Rule 17 and Schedule 2(g) update
27th Feb 20267:00 amRNSUpdate on Funding and Board change
7th Jan 20267:00 amRNSFull year trading and operational update
15th Dec 20253:26 pmRNSGrant of 2025 LTIP Awards
24th Sep 20257:00 amRNSHalf Year Report
17th Sep 20257:00 amRNSNotice of interim results presentations
4th Aug 202511:26 amRNSPDMR Dealing
4th Aug 20257:00 amRNSHalf Year Trading Update and Notice of Results
30th Jun 20255:03 pmRNSResult of AGM
19th Jun 20257:00 amRNSDirector/PDMR Shareholding
17th Jun 20257:00 amRNSDirector/PDMR Shareholding
16th Jun 20253:27 pmRNSDirector/PDMR Shareholding
16th Jun 202511:34 amRNSDirector/PDMR Shareholding
10th Jun 20257:00 amRNSNotice of Investor Presentation
6th Jun 20257:00 amRNSPosting of Annual Report and Notice of AGM
3rd Jun 20257:00 amRNSFinal Results
28th May 20257:00 amRNSNotice of Results
14th Apr 20257:00 amRNSContract Win
7th Apr 20257:00 amRNSTrading and Operational Update & Notice of Results
10th Feb 20257:00 amRNSSetcar secures a new contract win and a renewal
19th Nov 20247:00 amRNSAppointment of Nominated Adviser and Broker
25th Sep 20247:00 amRNSHalf-year Report
13th Sep 20247:00 amRNSNotice of Results
26th Jul 20244:33 pmRNSResult of General Meeting
4th Jul 20242:24 pmRNSNotification of major holdings
2nd Jul 20244:23 pmRNSNotification of major holdings
1st Jul 20243:16 pmRNSNotification of major holdings
28th Jun 20243:09 pmRNSDirectors’ Participation in Fundraising
28th Jun 20242:57 pmRNSHolding(s) in Company
28th Jun 202412:09 pmRNSPosting of Annual Report & Accounts
27th Jun 20243:50 pmRNSResult of AGM & GM
26th Jun 20247:00 amRNSFinal Results
24th Jun 20247:00 amRNSUpdate on Voting & Action to be Taken
12th Jun 20241:06 pmRNSPosting of Circular and Notice of General Meeting
11th Jun 202410:40 amRNSResult of Placing and Subscription
11th Jun 20247:00 amRNSProposed equity raise
3rd Jun 20247:00 amRNSNotice of AGM
29th May 20247:00 amRNSGipave selected for Rome 2025 Jubilee project
15th Apr 20243:01 pmRNSNotification of major holdings
12th Apr 20247:00 amRNSGiPave® installed at Imola Circuit
25th Mar 20247:00 amRNSEUR 1,000,000 Loan Agreement Signed
22nd Mar 20247:00 amRNSCollaboration with UK-based Heathcoat Fabrics
26th Feb 20247:00 amRNSAcquisition of 49% minority interest in Setcar

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.